The government has expressed interest in introducing an oral antiviral drug for COVID-19 by the end of the year, with Prime Minister Fumio Kishida saying that such treatments could become a “key trump card” in the prolonged, uphill battle against the coronavirus.
Japan’s vaccine rollout is set to start in less than two weeks. But with the rollout in other countries, including the U.S., not going as smoothly as authorities would have wanted, there are worries that it could be chaotic for Japan, too.
Government to compensate for side effects, in bid to secure stable supply
TOKYO — Japan’s government plans to cover compensation for any health problems that may arise here from coronavirus vaccines, seeking to ensure a stable supply from foreign manufacturers as global competition intensifies, Nikkei has learned.
Japanese drugmakers are accelerating their development of vaccines for the novel coronavirus even as foreign rivals seem to be leading the global race, with the government pushing homegrown efforts to secure stable supplies for the country.
The lead researcher in the trial being conducted for the flu drug Avigan said it’s too early to make a call on whether it works on COVID-19 and patients are still being enrolled.
The lack of results have raised doubts about its approval by the end of this month
Avigan, a candidate drug for treating COVID-19, has not shown apparent efficacy in treating the respiratory disease in clinical trials so far, raising doubts about its approval by the end of this month as sought by the government, sources familiar with the matter said Tuesday.
In the global hunt for coronavirus treatments, a Japanese antiviral medicine known as Avigan has won plaudits from Prime Minister Shinzo Abe and $128 million in government funding.
Drugmaker aims for trials this year with eventual goal of 10 million doses
Japanese drugmaker Shionogi & Co. said Monday that it is developing a coronavirus vaccine with the help of insects and aiming to start clinical trials this year.
The first coronavirus test kits made in Thailand are on their way to laboratories around the country after being delivered to Government House on Thursday (April 16). Developed by Siam Bioscience and the Department of Medical Science, the RT-PCR virus test kits meet World Health Organisation standards and will go straight into battle against the nationwide pandemic.
Le CNRS se mobilise pour vous donner des informations scientifiques fiables sur la pandémie du coronavirus COVID-19.
CNRS – Comment la recherche sur le SARS-CoV-2 s’est-elle organisée en Chine ?
Le virologue Dimitri Lavillette nous livre dans ce podcast son témoignage sur les débuts de l’épidémie, depuis l’Institut Pasteur de Shanghai où il mène ses travaux.
CNRS – Carte d’identité du virus SARS-CoV-2
Épidémie de COVID-19 : Carte d’identité du virus SARS-CoV-2 | Diffusons la science
Diffusons La Science
Série "Diffusons la Science", épisodes classés par thèmes. Un projet soutenu par la Direction de la Communication du CNRS.
Lettre d’information du CNRS N° Spécial Covid-19
COVID-19 的人文社會省思 / 中央研究院
Carnet Croisée de la BULAC : vues sur la pandémie
Atelier du CECMC – PANDÉMIES 大流行病
Carnet de l’EHESS : perspectives de sciences sociales sur le coronavirus
Publications sur le Covid-19 disponibles dans HAL
COVID-19 Dashboard
COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University
Worldometer
COVID-19 Coronavirus Pandemic
Santé Publique France
Infection au nouveau Coronavirus (SARS-CoV-2), COVID-19, France et Monde
Coronavirus pandemic: Tracking the global outbreak